EGFR and non-small cell lung carcinoma: According to recent studies, patients with NSCLC and EGFR mutations who underwent complete surgical resection and subsequently received oxitinib as targeted therapy had a significantly longer disease-free survival compared to those who were treated with a placebo (29).